William Blair analyst Sami Corwin maintained a Hold rating on Nkarta today. The company’s shares closed yesterday at $1.96.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Corwin covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ultragenyx Pharmaceutical, and PTC Therapeutics. According to TipRanks, Corwin has an average return of 0.2% and a 40.57% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nkarta with a $12.50 average price target.
NKTX market cap is currently $142.6M and has a P/E ratio of -1.33.
Read More on NKTX: